Remove Clinical Trials Remove Patients Remove Therapy
article thumbnail

Clinical Trial: Plant-Derived Cannabis Oil Effective for Patients with Fibromyalgia

NORML

"We conclude that phytocannabinoids can be a low-cost and well-tolerated therapy for symptom relief and quality of life improvement in these patients.". The post Clinical Trial: Plant-Derived Cannabis Oil Effective for Patients with Fibromyalgia appeared first on NORML.

article thumbnail

Clinical Trial: Oral THC Administration Associated with Opioid-Sparing Effects

NORML

Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. Sixty-six patients participated in the study. Half of the participants received dronabinol and the other half did not.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clinical Trial: Transdermal Application of CBD Effective in Patients with Myofascial Pain

NORML

The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine. Subjects receiving treatment reported no adverse effects.

article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

article thumbnail

Ehave, Inc. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board.

Cannabis Law Report

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board.